Importance of Candida species other than Candida albicans as opportunistic pathogens

Medical Mycology, Supplement

Volumn 36, Issue 1, 1998, Pages 156-165

  Coleman, D C ^a   Rinaldi, M G ^b   Haynes, K A ^c   Rex, J H ^d   Summerbell, R C ^e   Anaissie, E J ^f   Li, A ^e,g   Sullivan, D J ^a  

^a TRINITY COLLEGE DUBLIN   (Ireland)

^b UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^c HAMMERSMITH HOSPITAL   (United Kingdom)

^d UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

^e UNIVERSITY OF TORONTO   (Canada)

^f UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

^g Mycogenetics Inc   (Canada)

Author keywords

Antifungal therapy; Molecular analysis; Non C. albicans Candida; Opportunistic pathogens

Indexed keywords

ANTIFUNGAL AGENT;

CANDIDA; CANDIDA DUBLINIENSIS; CANDIDA GLABRATA; CANDIDIASIS; DRUG SENSITIVITY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MOLECULAR BIOLOGY; MYCOLOGY; OPPORTUNISTIC INFECTION; PATHOGENICITY; PHYLOGENY; REVIEW;

AIDS-RELATED OPPORTUNISTIC INFECTIONS; ANTIFUNGAL AGENTS; CANDIDA; CANDIDIASIS; HUMANS; OPPORTUNISTIC INFECTIONS; SPECIES SPECIFICITY; VIRULENCE;

EID: 33747136848     PISSN: 09668454     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (102)

1. Coleman DC, Bennett DE, Sullivan DJ. et al. Oral Candida in HIV infection and AIDS, new perspectives /new approaches. Crit Rev Microbiol 1993; 19: 61-82.
2. Wingard JR, Merz WG, Rinaldi MG. et al. Association of Torulopsis glabrata infections with fluconazole prophylaxis in neutropenic bone marrow transplant patients. Antimicrob Agents Chemother 1993; 37: 1847-9.
3. Fischer-Hoch SP, Hutwagner L. Opportunistic candidiasis: an epidemic of the 1980s. Clin Infect Dis 1995; 21: 897-904.
4. Hazen KC. New and emerging yeast pathogens. Clin Microbiol Rev 1995; 8: 462-78.
5. Fridkin SK, Jarvis WR. Epidemiology of nosocomial fungal infections. Clin Microbiol Rev 1996: 9: 499-511.
6. Perfect JR, Schell WA. The new fungal opportunists are coming. Clin Infect Dis 1996; 22 (Suppl. 2): S112-S118.
7. Sullivan DJ, Henman MC, Moran GP. et al. Molecular genetic approaches to identification, epidemiology and taxonomy of non-albicans Candida species. J Med Microbiol 1996; 44: 399-408.
8. Wingard JR, Merz WG, Rinaldi MG. et al. Increase in Candida krusei infection among patients with bone marrow transplantation and neutropenia treated prophylactically with fluconazole. N Engl J Med 1991; 325: 1274-7.
9. Schell WA. New aspects of emerging fungal pathogens: a multifaceted challenge. Clin Lab Med 1995; 15: 365-87.
10. Sullivan DJ, Westerneng TJ, Haynes KA, Bennett DE, Coleman DC. Candida dublmienits sp. nov. phenotypic and molecular characterization of a novel species associated with oral candidosis in HIV-infected individuals. Microbiol 1995: 141: 1507-21.
11. Wingard JR. Importance of. Candida species other than C. albicans as pathogens in oncology patients. Clin Infect Dis 1995; 20: 115-25.
12. Ampel NM. Emerging disease issues and fungal pathogens associated with HIV infection. Emerging Infect Dis 1996; 2: 109-16.
13. Nguyen MH, Peacock JE, Morris AJ. et al. The changing face of candidemia' emergence of non- Candida albicans species and antifungal resistance. Am J Med 1996; 100: 617-23.
14. Pfaller MA. Nosocomial candidiasis: emerging species, reservoirs, and modes of transmission. Clin Infect Dis 1996; 22 (Suppl. 2): S89-S94.
15. Coleman DC, Sullivan DJ, Bennett DE. et al. Candidiasis: the emergence of a novel species, Candida dubliniensis. AIDS 1997; 11:557-67.
16. Sullivan D, Haynes K, Bille J. et al. Widespread geographic distribution of oral Candida dubliniensis strains in human immunodeficiency virus-infected individuals. J Clin Microbiol 1997; 35: 960-4.
17. Odds FC. Candida and Candidosis. 2nd edn. London: Ballière Tindall 1988.
18. Powderly WG. Mucosal candidiasis caused by non-albicans species of Candida in HIV-positive patients. AIDS 1992; 6: 604-5.
19. Pfaller M, Wenzel R. Impact of the changing epidemiology of fungal infections in the 1990s. Eur J Clin Microbiol Infect Dis 1992; 11: 287-91.
20. Tang CM, Cohen J. Diagnosing fungal infections in immunocompromised hosts. J Clin Pathol 1992; 45: 1-5.
21. Pfaller MA. Epidemiology and control of fungal infections. Clin Infect Dis 1994; 19 (Suppl. 1): S8-S13.
22. Moran GP, Sullivan DJ, Henman MC. et al. Antifungal drug susceptibilities of oral Candida dubliniensis isolates from human immunodeficiency virus (HIV)-infected and non-HIV-infected subjects and generation of stable fluconazole-resistant derivatives in vitro. Antimicrob Agents Chemother 1997; 41: 617-623.
23. Chavanet P, Lopez J, Grappin M. et al. Cross-sectional study of the susceptibility of Candida isolates to antifungal drugs and in vitro-in vivo correlation in HIV-infected patients. AIDS 1994; 8: 945-50.
24. Johnson EM, Warnock DW, Luker J, Porter SR, Scully C. Emergence of azole drug resistance in Candida species from HIV-infected patients receiving prolonged fluconazole therapy for oral candidosis. J Antimicrob Chemother 1995; 35: 103-14.
25. Rex JH, Rinaldi MG, Pfaller MA. Resistance of Candida species to fluconazole. Antimicrob Agents Chemother 1995; 39: 1-8.
26. Coleman DC, Bennett DE, Gallagher PJ. et al. Oral candidiasis and HIV infection: antifungal drug resistance and changes in Candida population dynamics. In: Greenspan JS, Greenspan D, eds Oral Manifestations of HIV Infection. Chicago: Quintessence Publishing Co., Inc. 1995 112-118.
27. Goff DA, Koletar SL, Buesching WJ, Barnishan J, Fass RJ. Isolation of fluconazole-resistant Candida albicans from human immunodeficiency virus-negative patients never treated with azoles. Clin Infect Dis 1995; 20: 77-83.
28. Iwen PC, Kelly DM, Reed EC, Hinricks SH. Invasive infection due to Candida krusei in immunocompromised patients not treated with fluconazole. Clin Infect Dis 1995; 20: 342-7.
29. Fraser VJ, Jones M, Dunkel J. et al. Candidemia in a tertiary care hospital: epidemiology, risk factors, and predictors of mortality. Clin Infect Dis 1992; 15: 414-21.
30. Rex JH, Bennett JE, Sugar AM. et al. A randomized trial comparing fluconazole with amphotericin B for the treatment of candidemia in patients without neutropenia. N Engl J Med 1994; 331: 1325-30.
31. Nguyen MH, Peacock JE, Tanner DC. et al. Therapeutic approaches in patients with candidemia. Evaluation in a multicenter, prospective, observational study. Arch Intern Med 1995; 155: 2429-35.
32. Abi-Said D, Anaissie EJ, Uzun O. et al. The epidemiology of hematogenous candidiasis caused by different Candida species. Clin Infect Dis 1997; 24: 1122-8.
33. Pfaller MA, Bale MJ, Buschelman B, Rhomberg P. Antifungal activity of a new triazole, D0870, compared with four other antifungal agents tested against clinical isolates of Candida and Torulopsis glabrata. Diagn Microbiol Infect Dis 1994; 19: 75-80.
34. Martinez-Suarez JV, Rodriguez-Tudela JL. Patterns of in vitro activity of itraconazole and imidazole antifungal agents against Candida albicans with decreased susceptibility to fluconazole from Spain. Antimicrob Agents Chemother 1995; 39: 1512-6.
35. Rex JH, Cooper CR, Merz WG, Galgiani JN, Anaissie EJ. Detection of amphotericin B-resistant Candida isolates in a broth-based system. Antimicrob Agents Chemother 1995; 39: 906-9.
36. Rex JH, Pfaller MA, Barry AL, Nelson PW, Webb CD. Antifungal susceptibility testing of isolates from a randomized, multicenter trial of fluconazole versus amphotericin B as treatment of non-neutropenic patients with candidemia. NIAID mycoses study group and the candidemia study group. Antimicrob Agents Chemother 1995; 39: 40-4.
37. National Committee for Clinical Laboratory Standards. Reference method for broth dilution antifungal susceptibility testing of yeasts: proposed standard. M27-T. Wayne, Pa: National Committee for Clinical Laboratory Standards 1995.
38. Lozano-Chiu M, Nelson PW, Lancaster M, Pfaller MA, Rex JH. Lot-to-lot variability of antibiotic medium 3 when used for susceptibility testing of Candida isolates to amphotericin B. J Clin Microbiol 1997; 35: 270-2.
39. Pfaller MA, Barry AL. Evaluation of a novel colorimctric microbroth dilution method for antifungal susceptibility testing of yeast isolates. J Clin Microbiol 1994; 32: 1992-6.
40. Rex JH, Pfaller MA, Galgiani JN. et al. Development of interpretive breakpoints for antifungal susceptibility testing: conceptual framework and analysis of in vitro-in vivo correlation data for fluconazole, itraconazole, and Candida infections. Subcommittee on Antifungal Susceptibility Testing of the National Committee for Clinical Laboratory Standards. Clin Infect Dit 1997; 24: 235-47.
41. Korting HC, Ollert M, Georgii A, Fröschl M. In vitro susceptibilities and biotypes of Candida albicans isolates from the oral cavities of patients infected with human immunodeficiency virus. J Clin Microbiol 1988; 26: 2626-31.
42. Sangeorzan JA, Bradley SF, He X. et al. Epidemiology of oral candidiasis in HIV-infected patients: colonization, infection, treatment, and emergence of fluconazole resistance. Am J Med 1994; 97: 339-46.
43. Chryssanthou E, Torssander J, Petrini B. Oral. Candida albicans isolates with reduced susceptibility to fluconazole in Swedish HIV-infected patients. Scand J Infect Dis 1995; 27: 391-5.
44. Martins MD, Nelson PW, Lozazno-Chiu M, Rex JH. Incidence of symptomatic and asymptomatic carriage of fluconazole-resistant Candida in the oropharynx of HIV-infected patients. 34th Annual Meeting of the Infectious Diseases Society of America 1996 Abstract no. 82.
45. Markowitz M, Saag M, Powderly W. et al. A preliminary study of ritonavir, an inhibitor of HIV-I protease, to treat HIV-I infection. N Eng J Med 1995; 333: 1534-9.
46. Cohen J. Special report. AIDS Sci 1996; 272: 1876-83.
47. Lynch ME, Sobel JD. Comparative. in vitro activity of antimycotic agents against pathogenic vaginal yeast isolates J Med Vet Mycol 1994; 32: 267-74
48. Sobel JD, Vazquex JA. Symptomatic vulvovaginitis due to fluconazole-resistant Candida albicans in a female who was not infected with human immunodeficiency virus. Clin Infect Dis 1996; 22: 726-7.
49. Sobel JD, Chaim W. Treatment of. Candida glabrata vaginitis: a retrospective review of boric acid therapy. Clin Infect Dis 1997; 24: 649-52.
50. Phillips P, Shafran S, Garber G. et al. (Canadian Candidemia Study Group). Fluconazole (FLU) versus amphotericin B (AMB) for candidemia in non-neutropenic patients: a multicenter randomized trial. 35th Interscience Conference on Antimicrobial Agents and Chemotherapy 1995 Abstract no. LM20.
51. Anaissie EJ, Abi-Said D, Uzun O, Vartivatian SE. Prognostic factors for hematogenous candidiasis in cancer patients. 35th Interscience Conference on Antimicrobial Agents and Chemotherapy 1995 Abstract no. J31.
52. Weems JJ. Candida parapsilosis: epidemiology, pathogenicity, clinical manifestations, and antimicrobial susceptibility. Clin Infect Dis 1992; 14: 756-66.
53. Wingard JR, Dick JD, Merz WG. et al. Pathogenicity of Candida tropicalis and Candida albicans after gastrointestinal inoculation in mice. Infect Immun 1980; 29: 808-13.
54. Wingard JR, Dick JD, Merz WG. et al. Differences in virulence of clinical isolates of Candida tropicalis and Candida albicans in mice. Infect Immun 1982; 37: 833-6.
55. Walsh TJ, Merz WG. Pathologic features in the human alimentary tract associated with invasiveness of Candida tropicalis. Am J Clin Pathol 1986; 85: 498-502.
56. Rodriguez LJ, Rex JH, Anaissie EJ. Update on invasive candidiasis. Adv Pharmacol 1996; 137: 349-400.
57. Karyotakis NC, Anaissie EJ. Efficacy of escalating doses of liposomal amphotericin B (AmBisome) against hematogenous Candida lusitaniae and Candida krusei infection in neutropenic mice. Antimicrob Agents Chemother 1994; 38: 2660-2.
58. Sugar AM. Use of amphotericin B with azole antifungal drugs: What are we doing? Antimicrob Agents Chemother 1995; 39: 1907-12.
59. Nemunaitis J, Meyers JD, Buckner CD. et al. Phase I trial of recombinant human macrophage colony-stimulating factor in patients with invasive fungal infections. Blood 1991; 78:907-13.
60. Bodey GP, Anaissie E, Gutterman J, Vadhan-Raj S. Role of granulocyte-macrophage colony-stimulating factor as adjuvant therapy for fungal infection in patients with cancer. Clin Infect Dis 1993; 17: 705-7.
61. Spielberger RT, Falleroni MJ, Coene AJ, Larson RA. Concomitant amphotericin B therapy, granulocyte transfusions, and GM-CSF administration for disseminated infection with Fusariurn in a granulocytopenic patient. Clin Infect Dis 1993; 16: 528-30.
62. Henneqiun C, Benkerrou M, Gaillaird JL, Blanche S, Fraitag S. Role of granulocyte colony-stimulating factor in the management of infection with Fusarium oxysporum in a neutropenic child. Clin infect Dis 1994; 18: 490-1.
63. Barnett JA, Payne RW, Yarrow DY. Yeasts: Characteristics and Identification, 2nd edn. Cambridge: Cambridge University Press 1990.
64. Sullivan D, Bennett B, Henman M. et al Oligonucleotide fingerprinting of isolates of Candida species other than C. albicans and of atypical Candida species from human immunodeficiency virus-positive and AIDS patients J Clin Microbiol 1993; 31: 2124-33.
65. Williams DW, Wilson MJ, Lewis MAO, Potts AJC. Identification of. Candida species by PCR and restriction fragment length polymorphism analysis of intergenic spacer regions of ribosomal DNA. J Clin Microbiol 1995; 33: 2476-9.
66. Maiwald M, Kappe R, Sonntag HG. Rapid presumptive identification of medically important yeasts to the species level by polymerasc chain reaction and restriction enzyme analysis. J Med Vet Mycol 1994; 32: 115-22.
67. Lehmann PF, Wu LC, Pruitt WR, Meyer SA, Ahearn DG. Unrelatedness of groups of yeasts within the Candida haemulomi complex. J Clin Microbiol 1993; 31: 1683-7.
68. Lin D, Wu LC, Rinaldi MG, Lehmann PF. Three distinct genotypes within Candida parapsilosis from clinical sources. J Clin Microbiol 1995; 33: 1815-21.
69. Haynes KA, Westerneng TJ. Rapid identification of Candida albicans, C. glabrata, C. parapsilosis and C. krusei by species-specific PCR of large-subunit ribosomal DNA. J Med Microbiol 1996; 44: 390-6.
70. Fujita S, Lasker BA, Lott TJ, Reiss E, Morrison CJ. Microtitration plate enzyme immunoassay to detect PCR-amplified DNA from Candida species in blood. J Clin Microbiol 1995; 33: 962-7.
71. Dembry LM, Vazquez JA, Zervos MJ. DNA analysis in the study of the epidemiology of nosocomial candidiasis. Infect Control Hosp Epidemiol 1994; 15: 48-53.
72. Summerbell RC. The binomial test as a fundamental diagnostic method for medical mycology. J Clin Microbiol 1993; 31: 399-408.
73. Odds FC, Bemaerts R. CHROMagar Candida, a new differential isolation medium for presumptive identification of clinically important Candida species. J Clin Microbiol 1994; 32: 1923-9.
74. Rippon JW. Medical Mycology: The Pathogenic Fungi And The Pathogenic Actinomycetes, 3rd edn. Philadelphia: W.B. Saunders 1988.
75. Fonzi WA, Irwin MY. Isogenic strain construction and gene mapping in Candida albicans. Genetics 1993; 134: 717-28.
76. Togni G, Sanglard D, Monod M. Acid proteinase secreted by Candida troptcalis: virulence in mice of a proteinase negative mutant. J Med Vet Mycol 1994; 32: 257-65.
77. Kohler JR, Fink GR. Candida albicans strain heterozygous and homozygous for mutations in mitogen-activated protein kinase signaling components have defects in hyphal development. Proc Natl Acad Sci USA 1996; 93: 13223-8.
78. Leberer E, Harcus D, Broadbent ID. et al. Signal transduction through homologs of the Ste20p and Ste7p protein kinases can trigger hyphal formation in the pathogenic fungus Candida albicans. Proc Natl Acad Sci USA 1996; 93: 13217-22.
79. Sobel JD. Pathogenesis and epidemiology of vulvovaginal candidiasis. Ann NY Acad Sci 1988; 544: 547-57.
80. Rubenstein E, Lang R. Fungal endocarditis. Eur Heart J 1995; 16 (Suppl. B): 84-9.
81. Punt PJ, Oliver RP, Dingemanse MA, Pouwels PH, van den Hondel CH. Transformation of. Aspergillus based on the hygromycin B resistance marker from Escherichia coli. Gene 1987; 56: 117-24.
82. Sasnauskas K, Jomantiene R, Januska A. et al. Cloning and analysis of a Candida maltosa gene which confers resistance to formaldehyde in Saccharomyces cerevisiae. Gene 1992; 122: 207-11.
83. Sasnauskas K, Jomantiene R, Lebediene E. et al. Cloning and sequence analysis of a Candida maltosa gene which confers resistance to cycloheximide. Gene 1992; 116: 105-8.
84. Mehra RK, Thorvaldsen JL, Macreadie IG, Winge DR. Cloning system for Candida glabrata using elements from the metallothionein-IIa-encoding gene that confers autonomous replication. Gene 1992; 113: 119-24.
85. Kitada K, Yamaguchi E, Arisawa M. Cloning of the Candida glabrata TRP1 and HIS3 genes, and construction of their disruptant strains by sequential integrative transformation. Gene 1995; 165: 203-6.
86. Cole MF, Bowen WH, Zhao XJ, Cihlar RL. Avirulcnce of. Candida albicans auxotrophic mutants in a rat model of oropharyngeal candidiasis. Ferns Microbiol Lett 1995; 126: 177-80.
87. Gaskell J, Van-den-Wylenenberg A, Cullen D. Structure, inheritance and transcriptional effects of Pce1, an insertional element within Phanerochaete chrysosporium ligin peroxidase gene lip1. Proc Natl Acad Sci USA 1995; 92: 7465-9.
88. Cambereri EB, Helber J, Kinsey JA. Tad1-1, an active LINE-like element of Neurospora crassa. Mol Gen Gener 1994; 242: 658-65.
89. Kachroo P. Leong SA, Chatoo BB. Pot2, an inverted repeat transposon from the rice blast fungus Magnaportha grisea. Mol Gen Genet 1994; 245: 339-48.
90. Schiestl RH, Petes TD. Integration of DNA fragments by illegitimate recombination in Saccharamyces cerevisiae. Proc Natl Acad Sci USA 1991; 88: 7585-9.
91. Kuspa A, Loomis WF. Tagging developmental genes in Dictyostelium by restriction enzyme-mediated integration of plasmid DNA. Proc Natl Acad Sci USA 1992; 89: 8803-7.
92. Lu S, Lyngholm L, Yang G. et al. Tagged mutations at the Toxl locus of Cochliobolus heterostrophus by restriction enzyme-mediated integration. Proc Natl Acad Sci USA 1994; 91: 12649-53.
93. Brown DH, Slobodkin IV, Kumamoto CA. Stable transformation and regulated expression of an inducible reporter construct in Candida albicans using restriction enzyme-mediated integration. Mol Gen Genet 1996; 251: 75-80.
94. Hensel M, Shea JE, Gleeson C. et al. Simultaneous identification of bacterial virulence genes by negative selection. Science 1995; 269: 400-3.
95. Edman JC, Kovacs AJ, Masur H. et al. Ribosomal RNA sequence shows Pneumocystis carinii to be a member of the fungi. Nature 1988; 334: 519-22.
96. Coleman DC, Sullivan D, Haynes K. et al. Molecular and phenotypic analysis of Candida dubliniensis: a recently identified species linked with oral candidosis in HIV-infected and AIDS patients. Oral Dis 1997; 3 (Suppl. 1): in press.
97. Gilfillan GD, Sullivan DJ, Haynes K, Parkinson T, Coleman DC, Gow NAR. Candida dublimensis: phylogeny and putative virulence factors. Microbiology 1988, 144: 829-38.
98. Boerlin P, Boerlin-Petzold F, Durussel C. et al. Cluster of oral atypical Candida isolates in a group of human immunodeficiency virus-positive drug users. J Clin Microbiol 1995; 33: 1129-35.
99. McCullough M, Ross B, Reade P. Characterization of genetically distinct subgroup of Candida albicans strains isolated from oral cavities of patients infected with human immunodeficiency virus. J Clin Microbiol 1995; 33: 696-700.
100. Boucher H, Mercure S, Montplaisir S, Lemay G. A novel group I intron in Candida dubliniensis is homologous to a Candida albicans intron. Gene 1996; 180: 189-96.
101. Kurtzman CP, Robnett CJ. Identification of clinically important ascomycetous yeasts based on nucleotide divergence in the 5′ end of the large-subunit (26S) ribosomal DNA gene. J Clin Micmbiol 1997; 35: 1216-23.
102. Sullivan D, Coleman D. Candida dubliniensis: characteristics and identification. J Clin Microbial 1998; 36: 329-34.